NO314550B1 - Fremgangsmåte for fremstilling av et mutant herpesvirus - Google Patents

Fremgangsmåte for fremstilling av et mutant herpesvirus Download PDF

Info

Publication number: NO314550B1
Authority: NO; Norway
Prior art keywords: virus; gene; expression system; mutant; corresponding expression
Prior art date: 1990-09-25

Application number

NO19931057A

Other languages

English (en)

Norwegian (no)

Other versions

NO931057D0 (no

NO931057L (no

Inventor

Stephen Charles Inglis

Michael Edward Griff Boursnell

Anthony Charles Minson

Original Assignee

Cantab Pharma Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-25

Filing date

1993-03-23

Publication date

2003-04-07

1990-09-25 Priority claimed from GB909020799A external-priority patent/GB9020799D0/en

1991-03-08 Priority claimed from GB919104903A external-priority patent/GB9104903D0/en

1993-03-23 Application filed by Cantab Pharma Res filed Critical Cantab Pharma Res

1993-03-23 Publication of NO931057D0 publication Critical patent/NO931057D0/no

1993-05-03 Publication of NO931057L publication Critical patent/NO931057L/no

2003-04-07 Publication of NO314550B1 publication Critical patent/NO314550B1/no

Links

238000000034 method Methods 0.000 title claims description 31
241001529453 unidentified herpesvirus Species 0.000 title claims description 10
241000700605 Viruses Species 0.000 claims abstract description 165
108090000623 proteins and genes Proteins 0.000 claims abstract description 97
229960005486 vaccine Drugs 0.000 claims abstract description 40
208000015181 infectious disease Diseases 0.000 claims abstract description 34
238000004519 manufacturing process Methods 0.000 claims abstract description 24
230000002458 infectious effect Effects 0.000 claims abstract description 17
230000002950 deficient Effects 0.000 claims abstract description 9
108700005077 Viral Genes Proteins 0.000 claims abstract description 8
230000007547 defect Effects 0.000 claims abstract description 8
241000700584 Simplexvirus Species 0.000 claims description 30
230000003612 virological effect Effects 0.000 claims description 19
101150055782 gH gene Proteins 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
108090000288 Glycoproteins Proteins 0.000 claims description 10
102000003886 Glycoproteins Human genes 0.000 claims description 9
239000002773 nucleotide Substances 0.000 claims description 6
125000003729 nucleotide group Chemical group 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 2
238000004806 packaging method and process Methods 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 abstract description 31
239000013598 vector Substances 0.000 abstract description 11
230000002163 immunogen Effects 0.000 abstract description 10
230000001717 pathogenic effect Effects 0.000 abstract description 9
244000052769 pathogen Species 0.000 abstract description 6
241000894007 species Species 0.000 abstract description 3
230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 73
239000013612 plasmid Substances 0.000 description 37
108020004414 DNA Proteins 0.000 description 25
239000012634 fragment Substances 0.000 description 14
239000000427 antigen Substances 0.000 description 13
108091007433 antigens Proteins 0.000 description 13
102000036639 antigens Human genes 0.000 description 13
230000002238 attenuated effect Effects 0.000 description 12
108091026890 Coding region Proteins 0.000 description 11
108700039887 Essential Genes Proteins 0.000 description 11
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
238000002255 vaccination Methods 0.000 description 10
241000701022 Cytomegalovirus Species 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 8
230000028993 immune response Effects 0.000 description 8
230000010076 replication Effects 0.000 description 8
108700002232 Immediate-Early Genes Proteins 0.000 description 6
241000700618 Vaccinia virus Species 0.000 description 6
108010067390 Viral Proteins Proteins 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
230000003053 immunization Effects 0.000 description 6
239000011550 stock solution Substances 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 5
208000032420 Latent Infection Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 5
210000000609 ganglia Anatomy 0.000 description 5
238000002649 immunization Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
239000008272 agar Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000007969 cellular immunity Effects 0.000 description 4
108700004025 env Genes Proteins 0.000 description 4
101150030339 env gene Proteins 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
210000003501 vero cell Anatomy 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229960000380 propiolactone Drugs 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
101100296182 Caenorhabditis elegans paf-2 gene Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229940031567 attenuated vaccine Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
101150036031 gD gene Proteins 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000007420 reactivation Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000017613 viral reproduction Effects 0.000 description 2
229960004854 viral vaccine Drugs 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
241000700321 Herpes simplex virus (type 1 / strain SC16) Species 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
101150027427 ICP4 gene Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
241000700629 Orthopoxvirus Species 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
241000713311 Simian immunodeficiency virus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101800000385 Transmembrane protein Proteins 0.000 description 1
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
101800003344 Vaccinia growth factor Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000004880 explosion Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
101150118163 h gene Proteins 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
244000144980 herd Species 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000000856 sucrose gradient centrifugation Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19931057A 1990-09-25 1993-03-23 Fremgangsmåte for fremstilling av et mutant herpesvirus NO314550B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909020799A GB9020799D0 (en)	1990-09-25	1990-09-25	Viral vaccines
GB919104903A GB9104903D0 (en)	1991-03-08	1991-03-08	Viral vaccines
PCT/GB1991/001632 WO1992005263A1 (en)	1990-09-25	1991-09-23	Viral defective vaccine produced by transcomplementing cell line

Publications (3)

Publication Number	Publication Date
NO931057D0 NO931057D0 (no)	1993-03-23
NO931057L NO931057L (no)	1993-05-03
NO314550B1 true NO314550B1 (no)	2003-04-07

Family

ID=26297693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19931057A NO314550B1 (no)	1990-09-25	1993-03-23	Fremgangsmåte for fremstilling av et mutant herpesvirus

Country Status (19)

Country	Link
US (1)	US6541009B1 (fi)
EP (2)	EP0953648A3 (fi)
JP (1)	JP3895366B2 (fi)
KR (1)	KR100372934B1 (fi)
AT (1)	ATE194657T1 (fi)
AU (1)	AU658836B2 (fi)
BR (1)	BR9106879A (fi)
CA (1)	CA2091678C (fi)
DE (1)	DE69132311T2 (fi)
DK (1)	DK0550553T3 (fi)
ES (1)	ES2150416T3 (fi)
FI (1)	FI110438B (fi)
GB (1)	GB2263480B (fi)
GR (1)	GR3034484T3 (fi)
HK (1)	HK1001656A1 (fi)
MX (1)	MX9203717A (fi)
NO (1)	NO314550B1 (fi)
OA (1)	OA09777A (fi)
WO (1)	WO1992005263A1 (fi)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10399032I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
WO1990010693A1 (en) *	1989-03-08	1990-09-20	Health Research, Inc.	Recombinant poxvirus host selection system
US5837261A (en) *	1990-09-25	1998-11-17	Cantab Pharmaceuticals Research Limited	Viral vaccines
US5665362A (en) *	1990-09-25	1997-09-09	Cantab Pharmaceuticals Research Limited	Viral vaccines
US7374768B1 (en)	1990-09-25	2008-05-20	Xenova Research Limited	Viral vaccines
EP0953648A3 (en)	1990-09-25	2007-09-12	Cantab Pharmaceuticals Research Limited	Viral defective vaccine produced by transcomplementing cell line
EP0561034B1 (en) *	1991-08-26	1999-06-09	IMMUNO Aktiengesellschaft	Direct molecular cloning of a modified chordopox virus genome
TW289731B (fi) *	1992-07-09	1996-11-01	Akzo Nv
DE69333751T2 (de) *	1992-07-30	2005-12-29	Akzo Nobel N.V.	Nicht-verbreitendes lebendes herpesvirusvakzin
US7223411B1 (en)	1992-07-31	2007-05-29	Dana-Farber Cancer Institute	Herpesvirus replication defective mutants
ATE228008T1 (de) *	1992-07-31	2002-12-15	Harvard College	Herpesvirus impfstoffe
JPH08507784A (ja) *	1993-03-19	1996-08-20	キャンタブファーマシューティカルズリサーチリミティド	ウイルス・ワクチン
AU7192394A (en) *	1993-07-19	1995-02-20	Cantab Pharmaceuticals Research Limited	Production method for preparation of disabled viruses
WO1995004546A1 (en) *	1993-08-06	1995-02-16	Kai Juhani Ernst Krohn	Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
EP0659885A1 (en) *	1993-12-21	1995-06-28	Akzo Nobel N.V.	Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity
EP0758397B1 (en) *	1994-04-29	2005-06-22	Baxter Healthcare S.A.	Recombinant poxviruses with foreign polynucleotides in essential regions
US5807557A (en) *	1994-07-25	1998-09-15	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex
US6156319A (en) *	1994-07-25	2000-12-05	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex vaccine
GB9415369D0 (en) *	1994-07-29	1994-09-21	Lynxvale Ltd	Mutant virus
GB9415319D0 (en)	1994-07-29	1994-09-21	Medical Res Council	HSV viral vector
GB9423663D0 (en) *	1994-11-23	1995-01-11	Cantab Pharma Res	Viral preparations, immunogens, and vaccines
US6287557B1 (en) *	1995-02-21	2001-09-11	Cantab Pharmaceuticals Research Limited	Methods of gene therapy using herpes viral vectors expressing GM-CSF
JPH11502222A (ja) *	1995-03-23	1999-02-23	キャンタブファーマシューティカルズリサーチリミティド	遺伝子供給用ベクター
EP0828823A4 (en) *	1995-06-01	1999-02-10	Merck & Co Inc	HERPES SIMPLEX TYPE 1 VIRUS PROTEASE MUTANTS AND VECTORS THEREOF
EP0856062A2 (en) *	1995-10-19	1998-08-05	St. Jude Children's Research Hospital	Herpesvirus vectors and their uses
DE19709148C1 (de) *	1997-03-06	1998-09-03	Evotec Biosystems Gmbh	Verfahren zur Herstellung eines Impfstoffes gegen infektiöse Erreger
HUP0002922A3 (en)	1997-04-28	2003-03-28	Aventis Pharma Sa	Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
EP0884382A3 (en) *	1997-06-10	2000-10-25	Pfizer Products Inc.	Processes for preparation of marek's disease virus using continuous mammalian cell lines
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
GB9804632D0 (en)	1998-03-05	1998-04-29	Cantab Pharma Res	Virus preparations and methods
GB9808922D0 (en)	1998-04-24	1998-06-24	Cantab Pharmaceuticals Res Ltd	Virus preparations
US6225456B1 (en)	1998-05-07	2001-05-01	University Technololy Corporation	Ras suppressor SUR-5
US6506889B1 (en)	1998-05-19	2003-01-14	University Technology Corporation	Ras suppressor SUR-8 and related compositions and methods
US6399354B1 (en)	1998-07-31	2002-06-04	President And Fellows Of Harvard College	Replication-competent virus expressing a detectable fusion protein
GB9816761D0 (en)	1998-07-31	1998-09-30	Phogen Limited	Herpesvirus preparations and their uses
EP1153136A2 (en) *	1998-12-09	2001-11-14	The General Hospital Corporation	Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
US6441156B1 (en) *	1998-12-30	2002-08-27	The United States Of America As Represented By The Department Of Health And Human Services	Calcium channel compositions and methods of use thereof
GB9927353D0 (en) *	1999-11-19	2000-01-19	Cantab Pharma Res	Virus preparation and use
GB0018307D0 (en)	2000-07-26	2000-09-13	Aventis Pharm Prod Inc	Polypeptides
AU5345901A (en)	2000-04-13	2001-10-30	Univ Rockefeller	Enhancement of antibody-mediated immune responses
MXPA02011163A (es)	2000-05-10	2004-08-19	Mayo Foundation	Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
US7179614B2 (en)	2000-09-14	2007-02-20	Mount Sinai School Of Medicine	Screening methods to identify compounds that modulate type I phosphodiesterase (PDE) activity
US7060442B2 (en)	2000-10-30	2006-06-13	Regents Of The University Of Michigan	Modulators on Nod2 signaling
CN100422210C (zh)	2000-12-28	2008-10-01	Wyeth公司	来自肺炎链球菌的重组防护蛋白质
EP1499349B1 (en)	2001-03-02	2009-11-18	The Rockefeller University	Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
US7803982B2 (en)	2001-04-20	2010-09-28	The Mount Sinai School Of Medicine Of New York University	T1R3 transgenic animals, cells and related methods
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
US7432057B2 (en)	2004-01-30	2008-10-07	Michigan State University	Genetic test for PSE-susceptible turkeys
GB0408164D0 (en)	2004-04-13	2004-05-19	Immune Targeting Systems Ltd	Antigen delivery vectors and constructs
GB0716992D0 (en) *	2007-08-31	2007-10-10	Immune Targeting Systems Its L	Influenza antigen delivery vectors and constructs
US7604798B2 (en)	2004-07-15	2009-10-20	Northwestern University	Methods and compositions for importing nucleic acids into cell nuclei
WO2006020071A2 (en)	2004-07-16	2006-02-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Vaccines against aids comprising cmv/r-nucleic acid constructs
GB2421025A (en) *	2004-12-09	2006-06-14	Oxxon Therapeutics Ltd	HSV vaccination vectors
US7439327B2 (en)	2005-01-18	2008-10-21	Nuvelo, Inc.	Stem cell factor-like proteins and uses thereof
US8088382B2 (en)	2005-07-05	2012-01-03	Cornell Research Foundation, Inc.	Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US20100008944A1 (en) *	2005-07-29	2010-01-14	President And Fellows Of Harvard College	Herpes simplex virus mutant and uses therefore
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8093043B2 (en)	2008-06-04	2012-01-10	New York University	β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
CN102123732A (zh)	2008-06-20	2011-07-13	杜克大学	用于引发免疫应答的组合物，方法及试剂盒
RU2010151562A (ru)	2008-06-20	2012-07-27	ВАЙЕТ ЭлЭлСи (US)	Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
KR20110081282A (ko)	2008-11-05	2011-07-13	와이어쓰 엘엘씨	베타―용혈성 연쇄구균 (ｂｈｓ) 질환의 예방을 위한 다성분 면역원성 조성물
WO2010096561A1 (en)	2009-02-18	2010-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic hiv/siv gag proteins and uses thereof
US9186370B2 (en)	2010-03-19	2015-11-17	University Of South Alabama	Methods and compositions for the treatment of cancer
CA2808975C (en)	2010-08-23	2018-10-30	Wyeth Llc	Stable formulations of neisseria meningitidis rlp2086 antigens
JP5976652B2 (ja)	2010-09-10	2016-08-24	ワイス・エルエルシー	髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
US9458456B2 (en)	2011-04-01	2016-10-04	University Of South Alabama	Methods and compositions for the diagnosis, classification, and treatment of cancer
EP2691530B1 (en)	2011-06-10	2018-03-07	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
WO2013103401A1 (en)	2012-01-06	2013-07-11	University Of South Alabama	Methods and compositions for the treatment of cancer
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104334187B (zh)	2012-03-09	2017-04-05	辉瑞公司	脑膜炎双球菌组合物及其方法
JP6446377B2 (ja)	2013-03-08	2018-12-26	ファイザー・インク	免疫原性融合ポリペプチド
CA2940513C (en)	2013-03-11	2023-08-15	University Of Florida Research Foundation, Inc.	Delivery of card protein as therapy for ocular inflammation
WO2015033251A2 (en)	2013-09-08	2015-03-12	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
EP3049092A4 (en)	2013-09-24	2017-09-06	Duke University	Compositions, methods and kits for eliciting an immune response
BE1023557B1 (fr)	2014-02-10	2017-05-03	Univercells Sa	Systeme, appareil et procede pour la production de biomolecules
EP3107939B1 (en)	2014-02-19	2020-06-17	University of Florida Research Foundation, Inc.	Delivery of nrf2 as therapy for protection against reactive oxygen species
CN107249626A (zh)	2015-02-19	2017-10-13	辉瑞大药厂	脑膜炎奈瑟球菌组合物及其方法
KR102567845B1 (ko)	2017-01-31	2023-08-17	화이자 인코포레이티드	네이세리아 메닌기티디스 조성물 및 그의 방법
CA3062549A1 (en)	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
CA3061678A1 (en)	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
EP0213894A3 (en) *	1985-08-23	1987-10-21	Advanced Genetics Research Institute	Defective viral particle vaccines and methods for their use
US4996152A (en) *	1987-12-04	1991-02-26	The United States Of America, As Represented By The Secretary Of Agriculture	Avian herpesvirus amplicon as a eucaryotic expression vector
CH684094A5 (de) *	1988-03-21	1994-07-15	Viagene Inc	Rekombinante Retroviren.
CA2002839C (en) *	1988-11-14	2000-10-10	Neal S. Young	Parvovirus capsids
JP3140757B2 (ja) *	1989-02-06	2001-03-05	デイナ・フアーバー・キヤンサー・インステイテユート	パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
WO1990010693A1 (en)	1989-03-08	1990-09-20	Health Research, Inc.	Recombinant poxvirus host selection system
FR2663228A2 (fr) *	1989-09-29	1991-12-20	Agronomique Inst Nat Rech	Composition immunisante contre la maladie de newcastle et procede de preparation.
CA2039921A1 (en) *	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
EP0953648A3 (en)	1990-09-25	2007-09-12	Cantab Pharmaceuticals Research Limited	Viral defective vaccine produced by transcomplementing cell line
DE69233158T2 (de) *	1991-03-07	2004-05-13	Connaught Technology Corp., Greenville	Gentechnologisch hergestellter stamm für impfstoffe
ATE228008T1 (de)	1992-07-31	2002-12-15	Harvard College	Herpesvirus impfstoffe

1991
- 1991-09-23 EP EP19990106514 patent/EP0953648A3/en not_active Withdrawn
- 1991-09-23 KR KR1019930700913A patent/KR100372934B1/ko active
- 1991-09-23 WO PCT/GB1991/001632 patent/WO1992005263A1/en active IP Right Grant
- 1991-09-23 DE DE69132311T patent/DE69132311T2/de not_active Expired - Lifetime
- 1991-09-23 ES ES91917033T patent/ES2150416T3/es not_active Expired - Lifetime
- 1991-09-23 CA CA 2091678 patent/CA2091678C/en not_active Expired - Lifetime
- 1991-09-23 DK DK91917033T patent/DK0550553T3/da active
- 1991-09-23 EP EP19910917033 patent/EP0550553B1/en not_active Expired - Lifetime
- 1991-09-23 AU AU86489/91A patent/AU658836B2/en not_active Ceased
- 1991-09-23 JP JP51739991A patent/JP3895366B2/ja not_active Expired - Fee Related
- 1991-09-23 BR BR9106879A patent/BR9106879A/pt not_active Application Discontinuation
- 1991-09-23 AT AT91917033T patent/ATE194657T1/de not_active IP Right Cessation
1992
- 1992-06-29 MX MX9203717A patent/MX9203717A/es unknown
1993
- 1993-03-23 GB GB9306044A patent/GB2263480B/en not_active Expired - Fee Related
- 1993-03-23 NO NO19931057A patent/NO314550B1/no not_active IP Right Cessation
- 1993-03-24 FI FI931309A patent/FI110438B/fi active
- 1993-03-25 OA OA60354A patent/OA09777A/en unknown
1995
- 1995-06-05 US US08/462,632 patent/US6541009B1/en not_active Expired - Fee Related
1998
- 1998-01-27 HK HK98100722A patent/HK1001656A1/xx not_active IP Right Cessation
2000
- 2000-09-26 GR GR20000402173T patent/GR3034484T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69132311T2 (de)	2000-12-14
JPH06504194A (ja)	1994-05-19
ATE194657T1 (de)	2000-07-15
FI931309A0 (fi)	1993-03-24
CA2091678C (en)	2003-04-22
EP0953648A2 (en)	1999-11-03
NO931057D0 (no)	1993-03-23
GB9306044D0 (en)	1993-06-02
WO1992005263A1 (en)	1992-04-02
GB2263480A (en)	1993-07-28
ES2150416T3 (es)	2000-12-01
AU658836B2 (en)	1995-05-04
HK1001656A1 (en)	1998-07-03
AU8648991A (en)	1992-04-15
NO931057L (no)	1993-05-03
MX9203717A (es)	1992-09-01
BR9106879A (pt)	1993-07-20
DK0550553T3 (da)	2000-10-23
EP0550553A1 (en)	1993-07-14
JP3895366B2 (ja)	2007-03-22
GR3034484T3 (en)	2000-12-29
EP0550553B1 (en)	2000-07-12
GB2263480B (en)	1994-07-20
DE69132311D1 (de)	2000-08-17
EP0953648A3 (en)	2007-09-12
FI110438B (fi)	2003-01-31
US6541009B1 (en)	2003-04-01
OA09777A (en)	1993-11-30
CA2091678A1 (en)	1992-03-26
KR100372934B1 (ko)	2003-12-24
FI931309A (fi)	1993-03-24

Legal Events

Date	Code	Title	Description
2011-07-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6541009B1 (en)	2003-04-01	Viral vaccines
US5665362A (en)	1997-09-09	Viral vaccines
Xiang et al.	1996	A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier
JP3602530B2 (ja)	2004-12-15	遺伝子操作したワクチン菌株
Rosenthal et al.	1987	Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes
Patel et al.	1996	Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene
US5698202A (en)	1997-12-16	Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6573090B1 (en)	2003-06-03	Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
NO833205L (no)	1983-09-08	Fremgangsmaate for modifisering av et virus for vaksineformaal
US5824318A (en)	1998-10-20	Avirulent herpetic viruses useful as tumoricidal agents and vaccines
WO1992003537A1 (en)	1992-03-05	Self-assembling replication defective hybrid virus particles
US11844833B2 (en)	2023-12-19	Expression system for expressing herpesvirus glycoprotein complexes
Watanabe et al.	2007	Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector
JP4044131B2 (ja)	2008-02-06	ヘルペスウイルスワクチン
Brehm et al.	1999	Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more α-genes: ICP4, ICP27, ICP22, and ICP0
AU725557B2 (en)	2000-10-12	Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US7374768B1 (en)	2008-05-20	Viral vaccines
RU2236256C2 (ru)	2004-09-20	Вакцина, содержащая мутантный вирус герпеса
CN1062601C (zh)	2001-02-28	病毒疫苗
Morghen et al.	2000	Virus vectors for immunoprophylaxis
WO2023245159A1 (en)	2023-12-21	Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
US20020086035A1 (en)	2002-07-04	Herpevirus replication defective mutants
CZ127394A3 (en)	1995-11-15	Replication-capable recombinant virus, process of obtaining thereof and vaccine composition
Kessler et al.	1998	Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector
WO1996016164A1 (en)	1996-05-30	Viral preparations, immunogens, and vaccines